Vilon (KE) record · updated 18h ago

Inflammation & immuneHealing & recoveryGrade B · human evidenceResearch use only

All 5 studies Jump to the evidence Compare

What is Vilon (KE) used for?

Vilon (KE), a dipeptide, is classified as a thymus immune bioregulator. Its primary mechanism of action involves modulation of immune responses, particularly through the influence on monocyte and macrophage activity. Research indicates that Vilon can regulate proliferative activity and inflammatory pathways in immune cells, which may have implications for conditions characterized by immune dysregulation.

Primarily researched for · Inflammation & immune

Development stage

where Vilon (KE) sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 1 registered trial. It describes the research record, not a recommendation.

Identity

NameVilon (KE)

Chain length—

Molecular weight275.3 Da

FormulaC11H21N3O5

Structure typeSmall molecule

ClassImmune

Research levelPreclinical

Discovered byCurated master list · 2026

Mass and formula from PubChem CID 7010502. No verified residue count for this compound.

Pharmacology

Mechanism—

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 9, 2026. How this works →

Research stats

Total studies5

Human / animal / cellular3 / 0 / 1

Highest trial phasePreclinical

Years covered2022–2025

Latest study2mo ago

Publication history

20222025

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 5 Semantic Scholar UniProt

Study register

5 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Evaluating Seismocardiography as a Non-Exercise Method for Estimating Maximal Oxygen Uptake. FindingCPET VO2MAX was 37.2 (8.6) mL/min/kg, n=94.	Human	2023	Full text read0.90
Auditory Spatial Perception as a Function of Recreational Noise Exposure in Gen-Z Adults with Normal Hearing. FindingNot reported in abstract.	Human	2024	Full text read0.80
Hyoid bone-based sex discrimination among Egyptians using a multidetector computed tomography: discriminant function analysis, meta-analysis, and artificial intelligence-assisted study. FindingAccuracies of machine learning models ranged from 0.8667 to 0.933.	Human	2025	Full text read0.80
Healthy microbiome-moving towards functional interpretation. FindingNot reported in abstract.	review	2025	Full text read0.70
Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. FindingNot reported in abstract.	In vitro	2022	Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Vilon (KE) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Vilon (KE) is discussed should be drawn from it.